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Abstract
Background: The human papilloma virus (HPV) infections were addressed with two FDA-approved HPV vaccines:
quadrivalent and bivalent vaccine. The objective of this manuscript is to determine the safety of the HPV vaccine.
Results: A search of PubMed articles for “human papillomavirus vaccine” was used to identify all-type HPV clinical
studies prior to October 2014. A refined search of clinical trials, multicenter studies, and randomized studies were
screened for only randomized controlled trials comparing HPV vaccine to controls (saline placebo or aluminum
derivatives). Studies were limited to the two FDA-approved vaccines. Following PRISMA guidelines, the literature
review rendered 13 publications that met inclusion/ exclusion criteria. Gender was limited to females in 10 studies
and males in 1 study. Two studies included both males and females. Of the 11,189 individuals in 7 publications
reporting cumulative, all-type adverse events (AE), the AE incidence of 76.52 % (n = 4544) in the vaccinated group
was statistically significantly higher than 67.57 % (n = 3548) in the control group (p < 0.001). The most common AE
were injection-site reactions. On the other hand, systemic symptoms did not statistically significantly differ between
the vaccination cohort (35.28 %, n = 3351) and the control cohort (36.14 %, n = 3198) (p = 0.223). The pregnancy/
perinatal outcomes rendered no statistically significant difference between the vaccine group and control group.
Conclusion: Because the statistically significantly higher incidence of AE in the HPV vaccine group was primarily
limited to injection-site reactions, the vaccinations are safe preventative measures in both males and females.
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Résumé
Contexte: Les infections dues au papillomavirus humain (HPV) ont été prises en compte par deux vaccins HPV
approuvés par la FDA (Food and Drug Administration: Agence américaine des Produits Alimentaires et
Médicamenteux): les vaccins quadrivalent et bivalent. L’objectif de cet article est de déterminer la sécurité du vaccin
HPV.
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Résultats: Une recherche dans PubMed des articles sur “human papillomavirus vaccine” a été utilisée pour identifier
tout type d’études cliniques sur HPV antérieures à Octobre 2014. Une recherche affinée des essais cliniques, des
études multicentriques et des études randomisées n’a été menée que pour les essais randomisés avec groupe
témoin comparant le vaccin HPV à un témoin (solution saline comme placébo ou dérivés de l’aluminium). Seules
les études utilisant les deux vaccins approuvés par la FDA ont été retenues. En suivant les recommandations
PRISMA, la revue de la littérature a retrouvé 13 publications conformes aux critères d’inclusion/exclusion. Dix études
impliquaient les femmes et une les hommes. Deux études incluaient à la fois des femmes et des hommes. Sur les
11 189 personnes de 7 articles rapportant tout type d’effets indésirables (EI) cumulés, l’incidence d’EI de 76,52%
(n=4544) dans le groupe vacciné était significativement plus élevée que l’incidence de 67,57% dans le groupe
témoin (p<0,001). Les réactions sur le site d’injection étaient l’EI le plus courant. D’autre part, les symptômes
systémiques ne différaient pas significativement entre la cohorte vaccinée (35,28%; n=3351) et la cohorte témoin
(36,14%; n=3198) (p=0,223). Les issues des grossesses et les issues périnatales n’étaient pas significativement
différentes entre groupe vacciné et groupe placébo.
Conclusion: Comme l’incidence significativement plus élevée d’EI dans le groupe vacciné se limitait principalement
aux réactions sur le site d’injection, les vaccinations sont des mesures préventives sans danger pour les hommes et
les femmes.
Mots clés: Bivalent, HPV, Papillomavirus humain, Vaccin, Quadrivalent
Background
The human papillomavirus (HPV) is an important
preventable cause of sexually-transmitted disease and
squamous cell carcinomas. HPV types 16 and 18 have
been implicated in cervical, anal, vaginal, and vulvar
cancers, while types 6 and 11 cause anogenital warts.
Between 2003 and 2004, the overall HPV prevalence was
26.8 % [1]. Moreover, the prevalence of HPV infections
statistically significantly increased with each year of age
from 14 to 24 (p < 0.001) [1]. The National Cancer Insti-
tute independently developed the HPV vaccine, which was
subsequently sold to Merek & Co and GlaxoSmithKline
for randomized controlled trials (RCTs). The HPV vaccine
studies were subsequently marketed as a novel interven-
tion to curtail the infection’s oncologic aptitude. Years
of clinical trials by the pharmaceutical companies have
materialized into two Food and Drug Administration
(FDA)-approved HPV vaccine. First, Gardasil or Silgard
(Merck & Co) is a human recombinant papillomavirus
vaccine- quadrivalent types 6,11,16,18. Second, Cervarix
(GlaxoSmithKline) is a bivalent human papillomavirus
vaccine- types 16, 18. While the efficacy of both vaccines
has been verified in randomized control studies (RCT)
[2–4], the safety of these prophylactic interventions has
been strongly contested in the outpatient settings.
Methods
The literature review followed Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA)
guidelines (Fig. 1) [5]. A search of PubMed articles
for “human papillomavirus vaccine” was used to identify
all-type HPV clinical studies prior to October 2014. A
refined search of clinical trials, multicenter studies, and
randomized studies were screened for only randomized
controlled trials comparing HPV vaccine to controls
(saline placebo or aluminum derivatives). With a compi-
lation of previously published RCTs, we compared adverse
effects from the HPV vaccine versus control injection.
The primary endpoint was to determine the safety of
the HPV vaccine. The literature review outlined in Table 1
includes the primary author, publication year, number
study participants, description of the study population,
type of adverse events, number of vaccinated and unvac-
cinated participants for whom adverse events (AE) are re-
ported, and P value comparison between the two cohorts.
Both solicited and unsolicited adverse events were
included in the review. AE were determined by the article
investigator as possibly, probably, or definitely related to
the vaccine. AE were categorized according to the discrete
time intervals during which the unintended outcome
occurred. HPV vaccine was typically administered in a
3-dose schedule. The number of adverse events was
expressed as a proportion of subjects, rather than the
proportion of doses.
Inclusion/ Exclusion criteria
Only randomized controlled trials were included in the
present article. Vaccination groups were limited to the
two FDA-approved HPV vaccinations: (1) quadrivalent
HPV-6,11,16,18 L1 virus-like particle (VLP) vaccine; (2)
HPV-16,18 Adjuvant System (AS) 04 vaccine. Vaccines are
composed of either quadrivalent or bivalent antigens plus
either an amorphous aluminum hydroxyphosphate sulfate
(AAHS) adjuvant or aluminum hydroxide [Al(OH)3]. Con-
trol cohorts were limited to solutions containing either (A)
saline placebo; or (B) identical components to those in the
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vaccine, with the exception of the HPV antigens. Twelve ar-
ticles included AAHS or Al(OH)3 placebo [2, 3, 6–15];
however, Reisinger et al. utilized a saline placebo [16]. RCTs
with hepatitis A and/or hepatitis B vaccine controls were
excluded [17–29]. Control groups without injections were
also removed from the literature review insomuch as the
study design would interfere with the blinded schema and
become susceptible to a reporting bias/ information bias
[30]. Randomized controlled trials without mention of ad-
verse events and/or non-clinical RCTs were excluded from
the literature review. Repeat studies, ad hoc subgroup ana-
lysis, and pooled analyses were similarly excluded [4, 31–
38]. Lastly, AE expressed as a percentage of doses, rather
than a percentage of study participants, were not included
in Table 1 [13].
Statistical analysis
Demographic information was described using summary
statistics. The percent of subjects who experienced an
AE in the vaccine group were compared to the placebo
counterparts with Chi-squared (χ2) tests. Stata (version
12.0, College Station, TX, USA) and GraphPad Software
were used for statistical interpretations of the raw data.
Statistical significance was set a p ≤ 0.05.
Results
The PRISMA flow diagram detailing the selection
process is presented in Fig. 1. The most common reason
for exclusion was non-randomized, clinical-controlled
trials (n = 230). Of the 86 RCTs, the most prevalent
exclusion criteria was non-clinical studies/ studies with-
out mention of AE (n = 29), followed by HPV RCTs with
vaccines other than the quadrivalent HPV-6,11,16,18 L1
VLP or bivalent HPV-16,18 AS04. Following PRISMA
guidelines, the literature review rendered 13 publications
that met the aforementioned inclusion/ exclusion criteria
[2, 3, 6–16, 39]. Most clinical studies were sufficiently
powered to detect a statistically significant difference
between the vaccination and control cohorts, with the
smallest study population of 150 women in the RCT by
Denny et al. [15].
In the present literature review, the study population
consisted of 31,289 subjects, 98.87 % of whom (n =
30,934) had follow-up data available for documentation
of adverse events. Gender was limited to females in 10
studies [2, 3, 6–10, 13–15] and males in 1 study [12].
Two studies included both males and females [11, 16].
Ages ranged from 9 to 45 years. The sample populations
were derived from multi-national institutions, with
PRISMA Flow Diagram































control trials excluded 
(n = 230)
Full-text articles 
assessed for eligibility 
(n = 86)
Full-text articles excluded, 
-Non-clinical studies/ studies without mention of adverse 
events (n = 29)
-Vaccines other than the quadrivalent HPV-6,11,16,18 L1 
VLP or HPV-16/18 AS04 vaccine (n = 18)
-Non-placebo control group, e.g., Hepatitis A or Hepatitis B 
vaccine (n = 13)
-Repeat articles (n = 9)
-Control group without a placebo injection (n = 1)Studies included in 
literature review 
(n = 15)
Studies included in 
quantitative synthesis
(n = 13)
Fig. 1 PRISMA Flow Diagram for publication selection
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Table 1 Literature review of vaccine-related adverse events reported from HPV vaccination in randomized controlled trials
Author, Year Study population Inclusion criteria Adverse events Vaccine group (%) Control group (%) P
Harper et al. 2004 [6] N = 1113 women from 32 study
sites in North America and Brazil.
15–25 years
≤6 lifetime sexual partners
No abnormal Pap test
No external condylomata
HPV 16/18 seronegative













































Entire study period (0–27 months)
Vaccine-related serious adverse event
Discontinuation for non-serious
adverse event















No abnormal Pap smears
≤4 lifetime sex partners




Vaccine-related serious adverse events

















Reisinger et al. 2007 [16] N = 1781 children from 47 sites in
10 countries in North America,
Latin America, Europe, and Asia,





No gross purulent cervicitis
No genital warts
No abnormal Pap smear
No cervical intraepithelial
neoplasia
≤4 lifetime sex partners
Non-pregnant





























N = 1157 N = 579
Fever 1074 (92.83) 541 (93.44) 0.638
Merck V501-013
FUTURE I Study
Garland et al. 2007 [2]
N = 5455 women at 62 study
sites in 16 countries, enrolled
from January 2002 to March 2003
16–24 year old
Non-pregnant
No history of genital warts
No abnormal cervical
cytology testing
≤4 lifetime sex partners
Effective contraception





























































N = 12,167 women in 13
countries, enrolled from June





≤4 lifetime sex partners
Effective contraception




























Muñoz et al. 2009 [8] N = 3819 women from 38
international sites in Colombia,
France, Germany, Philippines,




No genital warts or cervical
disease
HIV seronegative

















Bhatla et al. 2010 [9] N = 330 women at four teaching/
tertiary care hospitals across India,














Grade 3 solicited general symptoms






























































Entire study period N = 145 Cervarix N = 145 Al(OH)3
Abdominal pain, IBS, dizziness, headache
Pelvic inflammatory disease
Medically significant conditions


























Table 1 Literature review of vaccine-related adverse events reported from HPV vaccination in randomized controlled trials (Continued)
Levin et al. 2010 [11] N = 126 children HIV-seropositive
children
7–12 years old
HIV with CD4 ≥ 15 %
≥3 months HAART if
CD4 < 25 %
14-day period N = 96 Gardasil N = 30 Saline Placebo
Adverse events
























Giuliano et al. 2011
[12, 39]
N = 4065 males from 71 sites in
18 countries
16–26 years old
1–5 male or female sexual partners
No anogenital lesions




















































Sow et al. 2013 [13] N = 676 women in 2 centers in
sub-Saharan Africa (Senegal and





≤6 lifetime sexual partners
0–12 months* N = 450 Cervarix N = 226 Al(OH)3
Grade 3 injection-site pain
Serious adverse eventc
Medically significant condition
New onset chronic disease
New onset autoimmune disease
Deaths


























No previous abnormal Pap
smears
≤4 males sex partners
Effective contraception

























Denny et al. 2013 [15] N = 150 women at a single
center in Khayelitsha, Cape Town,
Republic of South Africa.
18–25 years old
≤6 lifetime sexual partners
Non-pregnant
Intact cervix
30-day period N = HIV 61 (+)/30 (-) Cervarix N = 59 HIV(+) Al(OH)3
Unsolicited adverse event
Headache
Upper respiratory tract infection
Lobar Pneumonia (Grade 3)
Bacterial Pneumonia (Grade 3)
53 (86.89)/ 26 (86.67)
12 (19.67)/ 4 (13.33)
10 (16.39)/ 7 (23.33)

























Table 1 Literature review of vaccine-related adverse events reported from HPV vaccination in randomized controlled trials (Continued)
Up to 7 months
Medically significant adverse
event
18 (29.51)/5 (16.67) 21 (35.59) 0.477/0.063











Statistically significant values are in bold
*Number of adverse events expressed as a function of the number of doses, rather than the number of patients, were excluded. These adverse events included malaria, headache, dysmenorrhea, abdominal pain,
vertigo, cough, nasopharyngitis
Amorphous aluminum hydroxyphosphate sulfate (AAHS) adjuvant; aluminum hydroxide [Al(OH)3]
aBronchospasm 1 day after the third dose
bSerious adverse events in the vaccine group were gastroenteritis, headache, hypertension, injection-site pain, and decrease in joint movement at the injection site
cSerious adverse events in both the vaccinated and control groups were likely due to malaria infection, unrelated to the vaccine
dElective discontinuation in the vaccine group was due to spontaneous abortion, unrelated to the vaccine
eElective discontinuation in the vaccine group was due to vaccine-related malaise and headache














the exception of a Chinese trial by Ngan et al. and a
Japanese trial by Yoshikawa et al. [10, 14]. Similarly,
all trials were multi-center studies, with the exception
of a single-institutional RCT in Hong Kong [10]. The
most common study inclusion criteria were ≤4–6
lifetime sexual partners, no abnormal Papanicolaou
smears, non-pregnant, and no cervical infections/ ano-
genital warts. Women were encouraged to utilize effective
contraception. Two studies specifically focused on Human
Immunodeficiency Virus (HIV)-seropositive participants
[11, 15].
Of the 11,189 individuals in 7 publications reporting
cumulative, all-type adverse events[7, 8, 11, 12, 14–16],
the AE incidence of 76.52 % (n = 4544) in the vaccinated
group was statistically significantly higher than 67.57 %
(n = 3548) in the placebo group (p < 0.001). The most
common AE were injection-site reactions. In fact, of the
18,348 participants in 9 reporting articles [2, 3, 6–8, 11,
12, 14, 16], the 77.43 % of vaccinated subjects (n = 7355)
who experienced all-type injection-site reactions was
statistically significantly higher than the 67.70 % of
control subjects (n = 5991) (p < 0.001). The most common
injection-site reactions were pain, induration, and ery-
thema. On the other hand, systemic symptoms did not
statistically significantly differ between the vaccination
cohort (35.28 %, n = 3351) and the placebo cohort
(36.14 %, n = 3198) (p = 0.223). The most common systemic
symptoms included fatigue, headache, and fever. Ten
articles (n = 30,398) reported serious adverse events [2, 3,
6–9, 12–14, 16]. The incidence of 0.15 % (n = 23) in
the vaccination division did not statistically significantly
differ from 0.14 % (n = 20) in the control counterparts
(p = 0.774). Of the 23 subjects experiencing serious AE, 17
(73.91 %) were attributable to malaria infection, unrelated
to the vaccine, in the sub-Saharan Africa study by
Sow et al. [13]. Serious AE in the remaining 6 vaccinated
subjects included bronchospasm, acute pancreatitis,
lymph node tuberculosis, gastroenteritis, headache, and
hypertension. Only 4 patients (0.03 %) in the vaccine unit
[6, 12] and 7 patients (0.06 %) in the control unit [6, 7, 12,
14] discontinued the study due to adverse events (p =
0.367). Of the four elective terminations in the vaccine
group, three men cited vaccine-related malaise, headache,
and pyrexia in the publications by Giuliano et al. [12, 39]
and Yoshikawa et al. [14], whereas one woman expe-
rienced a spontaneous abortion in the publication by
Harper et al. [6], thought to be unrelated to the vaccine.
Twelve and seventeen individuals died in the vaccine
and control groups, respectively. Causes of death in the
vaccine cohort included pneumonia and sepsis, overdose
of an illicit drug, motor vehicle accident (6 persons),
pulmonary embolism, infective thrombosis, homicide,
and suicide, none of which were linked with the vaccine
[2, 3, 12].
Ngan et al. and Sow et al. reported new-onset chronic
disease/ autoimmune disease following injection with
drug vs control [10, 13]. Of the 966 enrollees in the two
studies, the rate of 3.36 % in the vaccine randomization
did not statistically significantly differ from 4.85 % in the
control randomization (p = 0.246). Lastly, while effective
contraception and non-pregnancy represented key selec-
tion criteria for most RCTs in the present literature
review, pregnancy was reported in the follow up period.
Birth complications included one spontaneous abortion,
nine elective abortions, and one death of a premature
infant in the vaccination cohort in comparison to one
spontaneous abortion, one miscarriage, one ectopic
pregnancy, three elective abortions, and one death of
a premature infant in the control cohort. None of these
experiences were liked with the injections. The pregnancy/
perinatal outcomes from the Females United to Unila-
terally Reduce Endo/Ectocervical Disease (FUTURE) I
(Merck V501-013), FUTURE II (Merck V501-015), Merck
V501-016, and Merck V501-018 RCTs were combined in
the Appendix in the FUTURE II study (Merck V501-016,
018 did not meet selection criteria in this literature review)
[38]. In brief, no statistically significant difference was
observed between the vaccine group and control group.
Discussion
In 1796, an English physician, Edward Jenner, performed
the first vaccination by inoculating an 8-year-old boy
with pus from a cowpox lesion [40]. Despite the growing
safety concerns for his experimental design of a smallpox
vaccine, Dr. Jenner published his conclusions in a land-
mark text in the annals of medicine: Inquiry into the
Causes and Effects of the Variolae Vaccine [41]. Since the
development of Dr. Jenner’s time-honored work, vaccine
production over the ensuing centuries have ushered in
a new era of preventive medicine; nevertheless, safety
concerns for vaccination of children and young adults
still remains the greatest barrier to these scientific advan-
cements. A testament to this belief today, the most recent
FDA-approved vaccines, Gardasil/Silgard and Cervarix,
have met significant resistance owing to the fear of
unknown side-effects. In this literature review, we com-
pared adverse effects from the HPV vaccine versus control
injection from a compilation of published randomized
controlled trials. The primary endpoint of this study was
to determine the safety of the HPV vaccine.
In the present literature review, the vaccine was well-
tolerated without undue AE. All-type AE and injection-
related AE were the only two parameters with a signifi-
cantly higher rate in the HPV vaccinated subjects, whereas
systemic events, serious AE, and death did not differ. The
vaccine cohort (76.52 %) carried an approximately 10 %
higher rate of all-type adverse events in comparison to the
control cohort (67.57 %) (p < 0.001). These results
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corroborate a sub-analysis by Moreira et al. [39], who
reviewed AE in the 4065 males enrolled in the HPV RCT,
V501-20 published by Giuliano et al. [12]. The 1945 males
randomized to the Gardasil unit experienced a statistically
significantly higher rate of all-type AE (63.86 %) versus
AAHS adjuvants (58.15 %) (p < 0.001). In fact of the 7
publications reporting all-type adverse events, 5 found a
significant difference between the two cohorts [7, 8, 12,
14, 16]. The remaining two articles reporting no difference
were limited by a cohort size of less than 100 persons
[11, 15]. The most common AE was injection-site reac-
tions, such as pain, erythema, and induration. In the
present literature review, all-type injection-site reactions
were statistically significantly higher in the vaccine arm
(77.43 %) than the control arm (67.70 %) (p < 0.001). How-
ever, true injection-site, hypersensitivity reactions occur
infrequently, according a retrospective review of 380,000
doses of Gardasil administered to 12–26 year-old females
in Victoria and South Australia [42]. In that study, only
35 females had suspected hypersensitivity reactions.
Moreover, Kang et al. concluded that “only three of the 25
evaluated schoolgirls had probable hypersensitivity to the
quadrivalent human papillomavirus vaccine [42].” Several
authors contend that the causes of the general injection-
site reactions, and the hypersensitivity experiences speci-
fically, are not completely attributable to the antigenic
components of the vaccine, but rather due in part to the
aluminum additives [39, 42]. In the RCT by Reisinger
et al. (Table 1), the placebo group was given saline injec-
tions, from which only half of participants experienced
injection-site reactions [16]. By comparison, the frequency
of injection-site reactions averages at 68.95 % in control
arms with Al(OH)3 or AAHS and 77.43 % in the vacci-
nated arm, per the set literature review. Such a gradient
effect suggests that the aluminum products contribute to
the reactogenicity of the vaccine [39].
Systemic events did not differ in the vaccine division
(35.28 %) versus the control division (36.14 %) (p =
0.223); furthermore, most reported symptoms were mild
or moderate in intensity. Fatigue, headache, and pyrexia
were most commonly documented throughout the
follow up period. Delayed in onset, these experiences
likely reflect the initial innate immunologic response
followed by a sustained, adaptive response. Yoshikawa
et al. did detect a statistically significant difference of
all-type adverse events between the vaccine arm and
control arm (p < 0.001) (Table 1) [14]. The most com-
mon AE was injection-site adverse event, among which
pain was the most frequent symptom. Systemic AE were
the next most common event, although no statistically
significant difference was detected between the vaccine
and control cohorts (p = 0.260). Greater than 90 % of
those systemic AEs were of “moderate intensity,” with-
out any specification.
Serious AE in the present study did not statistically
significantly differ between the vaccine (0.15 %) and con-
trol (0.14 %) groups (p = 0.774) in the present literature
review. Commensurate with our findings, Roumbout et al.
reported no difference in serious AE in a systematic
review of six HPV trials (Peto odds ratio 1.00; 95 % CI
0.87–1.14). Death between the two arms did not differ
(Peto odds ratio 0.91; 95 % CI 0.39–2.14) [43]. In the
aforementioned review by Roumbout et al. as well as the
present review, motor vehicle accidents were the most
common cause of death. No mortalities were associated
with the vaccine.
Conclusion
Following PRISMA guidelines, the literature review
rendered 13 randomized controlled trials comparing HPV
vaccine to control. Of the 11,189 individuals in 7 publica-
tions reporting cumulative, all-type adverse events, the
vaccinated group was statistically significantly higher than
the control group, although the most common AE were
injection-site reactions. On the other hand, systemic
symptoms did not statistically significantly differ. The
pregnancy/ perinatal outcomes rendered no statistically
significant difference between the vaccine group and con-
trol group. Thus, the vaccinations are safe preventative
measures for both males and females.
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